CURE Global X S&P Biotech ETF
- 48.770
- +0.080+0.16%
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and More
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
A Look Into Incyte Inc's Price Over Earnings
Peering Into United Therapeutics's Recent Short Interest
Incyte Analyst Ratings
CareDx Stock Climbs 7% Amid Reports Natera Not Pursuing Litigation
Sarepta Therapeutics Analyst Ratings
Alnylam Pharmaceuticals Analyst Ratings
AbbVie Snaps Six Days of Losses, Trades in the Green
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Insmed Analyst Ratings
(EXAS) - Analyzing Exact Sciences's Short Interest
AbbVie's Options: A Look at What the Big Money Is Thinking
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams